Comparing first-line therapies in BRAF-mutated thyroid cancer using real-world data

Learn how Eisai collaborated with Tempus to generate the first large-scale, real-world evidence comparing first-line therapies for BRAF-mutated thyroid cancer, providing novel insights into the treatment landscape.

Sep 03, 2026
Life Sciences
Case Study

Related content

Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract digital representation of genetic code with glowing circular data visualization.

Foundation models in pathology: How Virchow is accelerating precision drug development

2026-08-27
Life Sciences
Foundation Model
Digital Pathology
pFM
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Person works on computer with abstract digital code and data patterns overlayed.

Bridging the gap: How Target Trial Emulation transforms real-world data into credible evidence

2026-08-20
Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract digital background with glowing white lines and a fading dotted pattern.

Q&A: Predicting response and resistance in ADCs with AI and multimodal data

2026-08-20
Life Sciences